BTT 3033 |
| Katalog-Nr.GC50075 |
BTT 3033 ist ein oral aktiver konformationsselektiver Inhibitor von α2β1 (EC50: 130 nM) durch Bindung an die α2I-Domäne.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1259028-99-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Selective inhibitor of integrin α2β1 (EC50 = 130 nM for α2β1 binding to collagen I). Binds to the α2I domain. Exhibits selectivity for α2β1 over integrins α3β1, α4β1, α5β1 and αv. Inhibits platelet aggregation to collagen I coated capillaries under flow. Also inhibits binding of α2-expressing CHO cells to collagen I under shear stress conditions.
Nissinen et al (2012) Novel a2 beta 1 integrin inhibitors reveal that integrin binding to collagen under shear stress conditions does not require receptor preactivation. J.Cell Biol. 287 44694 PMID:23132859
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *